Challenges to Implementation

author: Jonathan D. Quick, Management Sciences for Health, University of Cambridge
author: Gareth O. Williams, Marks & Clerk LLP
author: Gary S. Cooper, Goodwin Procter LLP
author: Yuri Dikhanov, The World Bank
published: March 20, 2013,   recorded: August 2004,   views: 2500
Categories

Related Open Educational Resources

Related content

Report a problem or upload files

If you have found a problem with this lecture or would like to send us extra material, articles, exercises, etc., please use our ticket system to describe your request and upload the data.
Enter your e-mail into the 'Cc' field, and we will keep you updated with your request's status.
Lecture popularity: You need to login to cast your vote.
  Bibliography

Description

In this concluding panel about international drug pricing, speakers discuss the legal pitfalls and complexities involved in global pharmaceutical trade. Gareth Williams notes that the implementation of the key TRIPS agreement (an international law that helps defend intellectual property) has been slow. The law “cannot prevent nations from taking steps to protect public health,” and its implementation regarding drug patents has been delayed until 2016 for developing nations. The European Union has created a “fortress Europe,” where you can’t import products from outside the community. Gary Goodwin cautions conference attendees against chatting even informally about drug prices, lest they be viewed by authorities as colluding. Competition watchdogs are increasingly sensitive to the possibility that pharmaceutical industry representatives engage in price-fixing schemes whenever they meet—including public forums such as this. “Any suggestion that pharmaceutical companies today should reach consensus on a pricing formula they might use or advocate, would be problematic and should not be entertained.” Yuri Dikhanov describes efforts within the World Bank to create sophisticated formulas by which to calculate the wealth, income and purchasing power not only of different nations but of their citizens. One part of this enterprise is the International Comparison Project, which attempts to gauge 1000-plus prices for products and services across 150 countries. This “very complex aggregate” would form the basis for an index that might ultimately enable more equitable and realistic price-setting for medicines internationally.

Link this page

Would you like to put a link to this lecture on your homepage?
Go ahead! Copy the HTML snippet !

Write your own review or comment:

make sure you have javascript enabled or clear this field: